Biowatch, thanks for the heads up. Things certainly are looking good for Liraglutide. I actually sold the rest of my AMLN after they recently announced yet another financing. I have lost faith in management and LAR, and could not conceive of holding on simply for Pramlintide (Symlin) for obesity, which has some potential.
Market Data 
Markets 
AI
